Invesco
ALT icon

Invesco’s Altimmune ALT Stock Holding History

Invesco’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
332,592
+104,735
+46% +$313K ﹤0.01% 2917
2026
Q1 		$702K Buy
227,857
+13,033
+6% +$55.3K ﹤0.01% 3013
2025
Q4 		$776K Buy
214,824
+52,881
+33% +$231K ﹤0.01% 3022
2025
Q3 		$611K Buy
161,943
+55,080
+52% +$213K ﹤0.01% 3152
2025
Q2 		$414K Buy
106,863
+25,735
+32% +$139K ﹤0.01% 3245
2025
Q1 		$406K Sell
81,128
-165,958
-67% -$1.05M ﹤0.01% 3239
2024
Q4 		$1.78M Buy
247,086
+215,375
+679% +$1.65M ﹤0.01% 2658
2024
Q3 		$195K Buy
31,711
+968
+3% +$6.56K ﹤0.01% 3524
2024
Q2 		$204K Buy
30,743
+2,986
+11% +$22K ﹤0.01% 3617
2024
Q1 		$283K Sell
27,757
-718,424
-96% -$7.31M ﹤0.01% 3547
2023
Q4 		$8.39M Buy
746,181
+713,152
+2,159% +$2.98M ﹤0.01% 1930
2023
Q3 		$85.9K Buy
33,029
+4,956
+18% +$14.2K ﹤0.01% 3740
2023
Q2 		$99.1K Buy
+28,073
New +$126K ﹤0.01% 3728
2023
Q1 		– Sell
-425,849
Closed -$7.01M – 3868
2022
Q4 		$7.01M Buy
+425,849
New +$4.78M ﹤0.01% 2069
2022
Q2 		– Sell
-12,318
Closed -$75K – 4036
2022
Q1 		$75K Buy
12,318
+487
+4% +$3.59K ﹤0.01% 3890
2021
Q4 		$108K Sell
11,831
-1,109
-9% -$11.8K ﹤0.01% 3892
2021
Q3 		$147K Buy
12,940
+2,502
+24% +$30.4K ﹤0.01% 3870
2021
Q2 		$103K Sell
10,438
-402,385
-97% -$5.5M ﹤0.01% 3888
2021
Q1 		$5.83M Sell
412,823
-292,575
-41% -$4.73M ﹤0.01% 2295
2020
Q4 		$7.96M Buy
705,398
+269,439
+62% +$3.17M ﹤0.01% 1927
2020
Q3 		$5.75M Buy
435,959
+206,300
+90% +$4.12M ﹤0.01% 1943
2020
Q2 		$2.46M Buy
+229,659
New +$1.26M ﹤0.01% 2379
2017
Q1 		– Sell
-329
Closed -$320K – 3695
2016
Q4 		$320K Buy
+329
New +$295K ﹤0.01% 3435

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco's ALT Position: Q2 2026 in Review

Invesco increased its Altimmune (ALT) stake by 46% in Q2 2026, buying an estimated $313K and bringing the position to 332,592 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2917.

Invesco first reported a position in ALT in Q4 2016 and has held it in 23 quarters since. The position peaked at $8.39M in Q4 2023. 211 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Invesco held 332,592 shares of Altimmune worth $1.01M as of Q2 2026.
  • Invesco bought 104,735 Altimmune shares in Q2 2026, an estimated $313K.
  • Altimmune made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2917 holding.
  • Invesco first reported a position in Altimmune in Q4 2016 and has held it in 23 quarters since.
  • Invesco's Altimmune position peaked at $8.39M in Q4 2023.
  • 211 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.